Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Seeman, M. V. Search for Related Content PubMed Citation Articles by Seeman, M. V. Gender Schizophrenia Spectrum Disorders Atypical Neuroleptics Conventional Neuroleptics

Gender Differences in the Prescribing of Antipsychotic Drugs

OBJECTIVE: The aim of this article is to offer recommendations and rationale for gender-specific antipsychotic treatment. METHOD: The author summarizes reviews of recent literature in psychiatric clinical trials, pharmacology, drug safety, toxicology, obstetrics and gynecology, and pediatrics. RESULTS: The pharmacokinetics and pharmacodynamics of antipsychotic drugs differ in women and men and are influenced by gender-specific factors such as body build, diet, smoking, concurrent medication, exercise, substance use, and hormonal transitions. In general, and for some drugs in particular, women require lower doses in order to stay well. Because preliminary drug testing is not done in pregnant women, the issue of effective dosing during pregnancy is unstudied, and safety for fetuses and nursing infants may not become evident until a drug is widely used. Specific adverse effects on issues crucial to women (e.g., parenting) have not been well studied, but some side effects, such as weight gain, passivity, hypotension, and hyperprolactinemia, are reported to be particularly problematic for women. Some serious side effects are more often seen among women than among men. CONCLUSIONS: Optimal maintenance regimens of antipsychotics for women and men are not the same.

This article has been cited by other articles:

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, January 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Psychiatr Serv, July 1, 2007; 58(7): 983 - 990. [Abstract] [Full Text] [PDF]

				D. Yaeger, H. G. Smith, and L. L. Altshuler Atypical Antipsychotics in the Treatment of Schizophrenia During Pregnancy and the Postpartum Am J Psychiatry, December 1, 2006; 163(12): 2064 - 2070. [Full Text] [PDF]

				M. T. Ruiz Cantero and M. A. Pardo European Medicines Agency policies for clinical trials leave women unprotected. J. Epidemiol. Community Health, November 1, 2006; 60(11): 911 - 913. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us